Mubadala grows its life sciences portfolio with Envision Pharma investment

By Backend Office, Desk Reporter
Envision Pharma
Representational Image

After announcing its $700 million investment in US-based tech startup Reef Technology earlier, Abu Dhabi’s state-owned investment firm Mubadala Investment Company (Mubadala) along with a consortium of investors have worked together with European healthcare investment specialist Global Healthcare Opportunities to improve its investment in UK-based Envision Pharma Group.

Founded in 2011, Envision Pharma Group (Envision) supports biopharmaceutical and medical device companies commercialize new compounds through medical strategy, strategic publications planning, and medical communications delivery.

With the transaction, Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO) along with Envision’s existing management team and staff have increased their stakes in the group. The move will also see existing investor, French private equity investment firm Ardian exit Envision after a successful 4-year partnership with the group.

Envision’s flagship technology iEnvision, a global medical affairs platform, supports medical strategy, scientific communications internal/external research, and grant/request management activities to help pharmaceutical companies operate their businesses in line with various compliances.

Over the last 19 years, Envision has enjoyed outstanding year-on-year organic growth, with expansion supplemented via a number of key strategic acquisitions in medical strategy, Health Economics and Market Access, HEMA, and behavioral science-led communications.

Envision employs more than 800 people across 14 different offices and boasts of an ever-growing global presence with now extends to Japan, Australia, Serbia, and Hungary.

Post-transaction, Envision will engage in a substantial rollout of its iEnvision technology to widen its suite of platform solutions and strategic communications capabilities and expects to see an increased synergy between these two elements.

David Thompson, CEO Envision, said, “Having worked alongside GHO for 4 years, we are delighted they have chosen to extend and deepen the partnership in a new investment cycle. We see a clear commitment to expanding our reach across the healthcare services spectrum, most notably in medical affairs, with the ultimate goal of enhancing physicians’ abilities to improve patient outcomes.”

The Partners at GHO Capital commented, “We are delighted to continue our successful partnership with David and his management team. Envision is a company we know well and continue to believe in owing to its unique services and technology proposition. We look forward to supporting this ambitious team on their next phase of growth and in delivering Envision’s full potential as the go-to strategic partner in outsourced medical affairs, communications, and consulting services.”